Back to top
more

Unilever (UL)

(Delayed Data from NYSE)

$65.35 USD

65.35
3,344,676

-0.24 (-0.37%)

Updated Sep 10, 2024 04:00 PM ET

After-Market: $65.49 +0.14 (0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 16% (41 out of 250)

Industry: Soap and Cleaning Materials

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Prosus, Intuitive Surgical and Unilever

by Zacks Equity Research

Prosus, Intuitive Surgical and Unilever are included in this Analyst Blog.

John Blank headshot

August U.S. CPI Data: Global Week Ahead

by John Blank

Investors are on edge -- ahead of more key macro events -- that could shape the tone for trading in the weeks ahead.

Accenture and Unilever Collaborate on Generative AI Platform

by Zacks Equity Research

ACN's collaboration with UL marks a strategic move toward strengthening its position as a leader in digital transformation.

Best Growth Stocks to Buy for September 6th

by Zacks Equity Research

CARG, AEYE and UL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 6, 2024.

The Zacks Analyst Blog Highlights American Water Works, NiSource, Evergy, Unilever and Flowers Foods

by Zacks Equity Research

American Water Works, NiSource, Evergy, Unilever and Flowers Foods are part of the Zacks top Analyst Blog.

Zacks.com featured highlights include Erie Indemnity, Sprouts Farmers Market, Newmont and Unilever

by Zacks Equity Research

Erie Indemnity, Sprouts Farmers Market, Newmont and Unilever are part of the Zacks Screen of the Week article.

Ritujay Ghosh headshot

5 Defensive Stocks With the Most Upside as Market Volatility Returns

by Ritujay Ghosh

Defensive stocks like AWK, NI, EVRG, UL and FLO are a safe bet during times of market volatility.

Nilanjan Banerjee headshot

Volatility Concerns? Bet on 4 Low-Beta Stocks: ERIE, SFM, NEM, UL

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. ERIE, SFM, NEM and UL are well-poised to gain.

Unilever PLC (UL) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Unilever PLC (UL) have what it takes to be a top stock pick for momentum investors? Let's find out.

New Strong Buy Stocks for September 4th

by Zacks Equity Research

FLIC, MHO, SMFG, PED and UL have been added to the Zacks Rank #1 (Strong Buy) List on September 4, 2024.

Best Growth Stocks to Buy for September 4th

by Zacks Equity Research

CSGS, IBKR and UL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 4, 2024.

Unilever (UL) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Unilever (UL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Rajani Lohia headshot

Procter & Gamble (PG) Trades Near 52-Week High: Should You Buy?

by Rajani Lohia

Procter & Gamble (PG) witnesses consistent growth, with the stock creating new 52-week highs in less than two months.

Rajani Lohia headshot

Procter & Gamble (PG) Hits 52-Week High: Buy, Hold or Sell?

by Rajani Lohia

After Procter & Gamble (PG) hits a 52-week high, we assess whether the current level warrants an opportunity to accumulate shares, hold positions or book profits.

A. O. Smith (AOS) to Buy Pureit & Expand Presence in India

by Zacks Equity Research

A. O. Smith's (AOS) acquisition of Pureit is set to strengthen its product offerings and boost its position in the water treatment industry.

Best Income Stocks to Buy for December 5th

by Zacks Equity Research

UL, SMMF and TM made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 5, 2023.

Down -5.3% in 4 Weeks, Here's Why Unilever PLC (UL) Looks Ripe for a Turnaround

by Zacks Equity Research

Unilever PLC (UL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Sanghamitra Saha headshot

6 ETF Areas & Stocks to Win on Upbeat August Retail Sales

by Sanghamitra Saha

Retail sales in the United States grew 0.6% sequentially in August 2023, beating forecasts of a 0.2% advance.

Sanghamitra Saha headshot

ETF Areas & Stocks to Win on Upbeat July Retail Sales

by Sanghamitra Saha

Retail sales in the United States gained 0.7% sequentially in July of 2023, marking a fourth successive rise.

Zacks Industry Outlook Highlights Unilever, Church & Dwight, Procter & Gamble and Colgate-Palmolive

by Zacks Equity Research

Unilever, Church & Dwight, Procter & Gamble and Colgate-Palmolive have been highlighted in this Industry Outlook article.

Avisekh Bhattacharjee headshot

4 Soaps & Cleaning Materials Stocks to Gain as Industry Catches On

by Avisekh Bhattacharjee

The soap and cleaning materials industry benefits from revived demand trends, pricing actions, innovation, digital transformation and brand building. Players like UL, CHD, PG and CL look well-poised.

Are Consumer Staples Stocks Lagging McCormick & Company (MKC) This Year?

by Zacks Equity Research

Here is how McCormick (MKC) and Unilever PLC (UL) have performed compared to their sector so far this year.

Sanghamitra Saha headshot

4 Sector ETFs & Stocks to Win on March Retail Sales

by Sanghamitra Saha

In March 2023, U.S. retail sales experienced a 1% sequential decline, better than market expectations of a 0.4% decrease.

GSK Receives Regulatory Nod for Consumer Healthcare Demerger

by Zacks Equity Research

GSK progresses with the separation of its Consumer Healthcare business from biopharmaceuticals into a separate public company, Haleon, as it gets regulatory approval from the FCA.

Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug

by Zacks Equity Research

The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.